|
Originally published In Press as doi:10.1074/jbc.M201508200 on May 21, 2002
J. Biol. Chem., Vol. 277, Issue 31, 27829-27838, August 2, 2002
Transcriptional Regulation of the Pituitary Vasopressin V1b
Receptor Involves a GAGA-binding Protein*
Simona
Volpi §,
Cristina
Rabadan-Diehl ,
Niamh
Cawley¶, and
Greti
Aguilera
From the Section on Endocrine Physiology,
Developmental Endocrinology Branch, and the ¶ Section on
Cellular Neurobiology, Laboratory of Developmental Neurobiology,
NICHD, National Institutes of Health,
Bethesda, Maryland 20892
Received for publication, February 13, 2002, and in revised form, May 20, 2002
 |
ABSTRACT |
The role of CT repeats (inverted GAGA box) in the
rat vasopressin V1b receptor (V1bR) promoter in the transcriptional
regulation of this gene was studied in H32 hypothalamic cells, which
express endogenous V1bR. Transfection of a 2.5-kb V1bR fragment
(2161 bp upstream and 377 bp downstream of the proximal transcriptional start point) into a luciferase vector (V1bRp2.5-Luc)
results in promoter activity in these cells. The 670-bp proximal
promoter fragment containing the GAGA box showed maximal promoter
activity, whereas deletion of the GAGA box abolished transcription.
Drosophila GAGA-binding protein increased V1bR promoter
activity by 11-fold when cotransfected with V1bRp2.5-Luc and
increased endogenous V1bR expression. Electrophoretic mobility shift
assay showed specific binding of pituitary nuclear extracts to
radiolabeled GAGA oligonucleotides, which increased following
restraint stress in rats, a condition associated with V1bR
up-regulation. DNA-binding activity involved a protein complex because
it was abolished by deoxycholate. Size-exclusion column chromatography
showed a complex of 127 kDa, which dissociated into ~70-kDa
components after deoxycholate/Nonidet P-40 treatment. This study
demonstrates that interactions of GAGA-binding proteins with the GAGA
box of the V1bR promoter activate V1bR gene expression and
provides a potential mechanism for physiological regulation of
V1bR transcription.
 |
INTRODUCTION |
The hypothalamic nonapeptide arginine vasopressin is an important
regulator of pituitary ACTH1
secretion (1, 2). The pituitary actions of vasopressin are mediated by
vasopressin receptors of the V1b subtype (V1bR), located in the plasma
membrane of the pituitary corticotroph (3). The vasopressin V1bR is a G
protein-coupled receptor associated with phospholipase
C/calcium/phospholipid-dependent signaling mechanisms (4).
This receptor is structurally different from the V1a receptor, which
mediates vasoconstrictor and metabolic actions of vasopressin, and the
V2 receptor responsible for water conservation in the kidney, which is
coupled to adenylate cyclase (5).
Previous studies have shown that a good correlation exists between
vasopressin binding and pituitary responsiveness, suggesting that the
number of vasopressin V1b receptors in the corticotroph plays an
important role in determining the sensitivity of the ACTH responses
during stress (6-8). To study the regulation of the V1bR, we (10) and
others (9) have recently isolated and characterized the 5'-flanking
region of the rat V1bR. Computer analysis of the putative promoter
region (bp 2161 to +377, corresponding to 2.1 kb of the putative
promoter, exon 1, intron 1, and 164 bp of exon 2) showed no TATA box,
but several potential sites for glucocorticoid, AP1, and cAMP
regulation. In addition, the promoter region of the rat V1bR includes
structural features not common in G protein-coupled receptors, such as
CA repeats (CACA box) and an unusually large stretch of 134 CT repeats
(inverted GAGA box).
GAGA repeats were first described in Drosophila heat shock
protein and histone gene promoters, where they were found to bind a
protein called the GAGA factor, encoded by the essential
Trithorax-like (Trl) gene (11-14). The GAGA
factor has been implicated in chromatin structure and remodeling and
normal expression of several developmental genes in
Drosophila (11, 15). Involvement of GAGA-binding protein in
transcription has also been reported for vertebrate genes such as the
serine protease inhibitor-2.1 gene, the type 1 angiotensin II
receptor gene, and the Xenopus stromelysin-3 gene (16-18).
The consensus GAGA binding sequence consists of ~3.5 GA
repeats, but longer repeats have been described in some promoters, including hsp26, hsp70, his3, and
his4 (13, 19).
Because the V1bR promoter contains a prominent GAGA box near the
transcriptional start point (10), in this study, we address the
question whether a GAGA-binding protein plays a role in V1bR transcription. Using V1bR promoter-driven luciferase constructs and a
Drosophila GAGA expression vector in rat H32 hypothalamic cells, which express endogenous V1b receptors, we provide evidence that
a GAGA-binding protein complex is involved in the transcriptional regulation of the V1bR.
 |
MATERIALS AND METHODS |
V1bR Promoter Constructs--
A construct containing a 2.5-kb
NcoI fragment of the V1bR gene from bp 2161 to +377 (+1
was assigned to the proximal transcriptional start point; corresponding
to 2.1 kb of the putative promoter, exon 1, intron 1, and 164 bp of
exon 2) cloned into the luciferase reporter vector pGL3-basic (Promega)
(10) was used to prepare the following restriction fragments of the
V1bR promoter: a 830-bp fragment (bp 453 to +377; obtained by
SmaI digestion) spanning the SmaI sites in the
multiple cloning site of the vector and bp 453 in the V1bR promoter
region, a 670-bp fragment (bp 294 to +377; produced by
BglII digestion) from the multiple cloning site to the
BglII site at bp 294 in the V1bR promoter, and a 470-bp
fragment (bp 90 to +377; obtained by digestion with MluII) from the multiple cloning site to BssHI at bp 90 in the
V1bR promoter region. The restriction fragments were separated on a 1%
agarose gel; the bands were excised; and the DNA was eluted using a
QIAquick gel extraction kit (QIAGEN Inc., Valencia, CA) and ligated
using T4 DNA ligase (Promega) into pGL3-basic to obtain the constructs
pGL3-V1bRp830, pGL3-V1bRp670, and pGL3-V1bRp470, respectively. An additional construct, pGL3-V1bRp830 GAGA (bp 453 to 303 and bp 90 to +377), was created by
BglII/BssHII digestion of pGL3-V1bRp830
and ligation after generation of blunt ends using Pfu
Turbo® (Stratagene).
The Drosophila GAGA factor cDNA was obtained by PCR from
a clone in the pET-14b vector (kindly provided by Dr. Jordi Bernues, Departamento de Biologia Molecular Cellular, Instituto de
Biologia Molecular, Barcelona, Spain). The cDNA fragment
(pCR3.1-GAGA construct) was generated using primers
5'-ggcagccatatgtcgctgccaa-3' (forward) and 5'-cgggctttgttagcagccggat-3'
(reverse), spanning 13 bp of the pET-14b vector and 9 bp of the
3'-untranslated region of Drosophila GAGA, and subcloned
into the mammalian expression vector pCR3.1 (Invitrogen). PCR was
performed using 100 ng of plasmid template DNA and 2.5 units of
Platinum® Pfx DNA polymerase (Invitrogen).
Amplification was performed using an initial cycle at 94 °C for 2 min, followed by 30 PCR cycles at 94 °C for 30 s, 65 °C for
1 min, and 72 °C for 1 min and a 10-min final extension at
72 °C.
The ligation reaction was used to transform TOP 10F' competent cells
(Invitrogen) following the manufacturer's protocol. All constructs
were purified using Wizard Plus® Miniprep (Promega) or
Maxiprep (QIAGEN) procedures. The accuracy of the PCR product was
verified by sequencing (Veritas, Rockville, MD).
Animal Procedures--
Male Sprague-Dawley rats (Harlan Sprague
Dawley, Inc., Indianapolis, IN) weighing 250-300 g were housed three
per cage in a controlled environment with free access to food and
water. After at least a 5-day stabilization period, rats were killed by
decapitation, and tissues were removed and rapidly frozen on dry ice
for preparation of nuclear extracts. To determine whether the
up-regulation of the V1bR observed after stress (6) is associated with
changes in GAGA-binding activity, groups of rats were subjected to
restraint stress for 15-90 min using 2.5 × 6-inch plastic
restrainers (20). Rats were killed by decapitation 15, 30, and 90 min
after initiation of the stress. Pituitaries were rapidly removed,
dissected from the neurointermediate lobes, and frozen in dry ice for
nuclear protein extraction. Fragments of liver from control and
stressed rats were collected as a control.
Cell Culture, Transfections, and Luciferase Assay--
The
hypothalamic cell line H32 (produced by Dr. Joachim Spiess, Max
Planck Institute for Experimental Medicine, Göttingen, Germany)
(21) was cultured in Dulbecco's modified Eagle's medium (Invitrogen)
containing 10% fetal bovine serum (Invitrogen), 10% horse serum, and
1% penicillin/streptomycin (Invitrogen). Preliminary experiments in
our laboratory using RT-PCR showed that this hypothalamic cell line
expresses V1bR mRNA.2
Cells were plated in 24-wells plates at a density of 20 × 103 cells/well and cultured at 37 °C under 5%
CO2 and 95% air. After 24 h of culture, cells were
transfected with 0.4 µg of DNA (pGL3-V1bRp (deletion constructs) or
the empty vector pGL3-basic) using LipofectAMINE Plus®
(Invitrogen). For cotransfection experiments, cells were transfected either with 0.4 µg of reporter plasmid pGL3-V1bRp, pGL3-V1bRp830, or
pGL3-V1bRp830 GAGA and 25-50 ng of pCR3.1-GAGA or the empty expression vector. After transfection, H32 cells were maintained in
Dulbecco's modified Eagle's medium with 2.5% fetal bovine
serum/horse serum for 24 h and then lysed using 1× reporter lysis
buffer (Promega) and processed for luciferase assay (Promega).
Evaluation of Transfection Efficiency by Southern
Blotting--
To determine whether differences in transfection
efficiency could account for the increases in promoter activity of the
V1bR promoter-luciferase deletion constructs, the amount of luciferase DNA was quantitated by Southern blot analysis after transfection of
pGL3-V1bRp2.5, pGL3-V1bRp830, and pGL3-V1bRp670 into H32 cells. A
33P-radiolabeled luciferase probe was prepared by random
primer labeling of a HindIII/XbaI restriction
fragment of pGL3-basic purified on a 1% agarose gel. Fifty ng of
luciferase DNA were denatured by heating for 3 min at 95 °C,
immediately placed on ice for 2 min, added to reaction mixture beads
(Ready-To-GoTM DNA labeling beads (without dCTP),
Amersham Biosciences) together with 50 µCi of
[ -33P]dCTP (PerkinElmer Life Sciences), and incubated
for 1 h at 37 °C. The labeled probe was purified using a
Sephadex G-25 column (Roche Molecular Biochemicals).
Cells plated in 10-mm Petri dishes to 70% confluence were transfected
with 4 µg of DNA. One day after transfection, cells were removed from
the dish and washed twice with phosphate-buffered saline, and the
pellets were resuspended in lysis buffer (87.5% Tris/EDTA (pH
8), 1% SDS, and 0.5 mg/ml proteinase K) and incubated overnight at
37 °C. Cellular DNA was purified by extracting three times with
phenol/chloroform/isoamyl alcohol (25:24:1), followed by ethanol
precipitation and resuspension in diethyl pyrocarbonate/water. Ten µg of DNA were digested with 20 units of NcoI enzyme
and separated on a 0.8% agarose gel containing 1× Tris
acetate/EDTA. DNA loading was quantified from the ethidium bromide
staining of the gel using Kodak 1D image analysis software.
For Southern blot analysis, the gel was washed with HCl (1:50) for 15 min, followed by 2 × 15-min rinses in DNA-denaturing solution and
2 × 10-min rinses in DNA-neutralizing solution (purchased from
Quality Biological, Inc., Gaithersburg, MD). DNA was transferred overnight from the gel into Tropilon PlusTM (positively
charged nylon membrane; Tropix Inc., Bedford, MA) by capillary using
10× SSC. After UV cross-linking, the membrane was incubated in
prehybridization buffer (50% formamide, 5× saline/sodium phosphate/EDTA, 5× Denhardt's solution, 0.5% SDS, and 0.1 mg/ml salmon sperm DNA) for 3 h at 42 °C. Hybridization was conducted overnight at 42 °C in the same buffer containing 2 × 107 dpm of the luciferase probe. The membrane was washed
twice at room temperature with 2× SSC and at 63 °C for 30 min with
2× SSC and 0.5% SDS. Bands were visualized and quantified using a
Molecular Dynamics PhosphorImager after overnight exposure at room temperature.
Preparation of mRNA and Quantitative RT-PCR--
For
quantitative RT-PCR of V1bR mRNA, cells were plated in 10-mm
culture dishes, transfected with 4 µg of pCR3.1-GAGA expression vector or the empty vector pCR3.1, and cultured for 24 h before mRNA isolation using RNAzolTM B (Tel-test, Inc.)
following the manufacturer's protocol. Poly(A)+ RNA was
isolated from the total RNA using oligo(dT) PolyATtract mRNA
isolation systems (Promega). RNA was subjected to digestion with 1 unit
of DNase I, Amplification Grade (Invitrogen) to eliminate contaminant endogenous DNA and quantified by UV spectrometry.
Five aliquots of each poly(A)+ preparation (50-100 ng)
were used for synthesis of double-stranded DNA and PCR amplification using the SUPERSCRIPTTM One-Step RT-PCR
PlatinumTM Taq system (Invitrogen) and rat V1bR
primers 5'-ggatgagaatgcccccaatgaaga-3' (forward) and
5'-gagagagagtggcccatacctaca-3' (reverse). Rat cyclophilin primers used
as internal controls were as follows: 5'-tgggaaggtgaaagaagg-3' (forward) and 5'-gctagacttgaaggggaatg-3' (reverse). Single-stranded cDNA was synthesized at 55 °C for 30 min, followed by 3 min at 94 °C. The five aliquots of each sample were subjected to a
different number of PCR cycles (20, 25, 30, 35, and 40) to determine
the linear range for quantification of the endogenous rat V1bR after transfection with Drosophila GAGA protein. Each cycle
consisted of 40 s at 94 °C, 40 s at 58 °C, and 40 s at 72 °C, followed by a 10-min extension at 72 °C. The PCR
products were separated and visualized on a 2% Tris
acetate/EDTA-agarose gel containing ethidium bromide and sized using
PCR markers (Promega). The image was captured electronically, and the
bands were quantified using Kodak 1D image analysis software.
Electrophoretic Mobility Shift Assay (EMSA)--
Nuclear
extracts from different rat tissues were prepared using
NE-PERTM nuclear and cytoplasmic extraction reagent
(Pierce) according to the manufacturer's protocol using a final
concentration of 2 mM phenylmethylsulfonyl fluoride (Sigma)
and 100× protease inhibitor mixture (Sigma). Protein concentration was
quantified by spectrophotometry using the Bio-Rad protein assay.
Double-stranded oligonucleotide probes were synthesized as
complementary single strands (Sigma) and annealed at 80 °C for 20 min, followed by slow cooling to room temperature overnight. Aliquots
of 25 pmol of GAGA or mutant GAGA double-stranded oligonucleotides were
end-labeled using T4 polynucleotide kinase (New England Biolabs Inc.)
and 50 pmol of [ -33P]ATP (PerkinElmer Life Sciences)
for 45 min at 37 °C in a total volume of 50 µl. The labeled GAGA
and mutant probes were purified by centrifugation on a Sephadex G-25
column. The sequences of the probes contained three to five GAGA
repeats, and upstream and downstream sequences flanking the GAGA box in
the V1bR promoter were as follows: GAGA probe,
GTGACA(GAGA)3 or (GAGA)5GGGAAA;
(GAGA)3 mutant probe,
GTGACAGTCACCGATTGTGGGAAA.
The incubation mixture contained 0.5-10 µg of nuclear extract, 25 mM HEPES (pH 7.9), 0.5 mM EDTA, 12.5 mM MgCl2, 10% glycerol, 1 mM
dithiothreitol, 125 mM KCl, 0.05 µg/µl poly(dI-dC), and
1 µg/µl bovine serum albumin (Sigma) in a total volume of 20 µl.
One ng of radiolabeled oligonucleotide was added to the reaction and
incubated for 20 min at room temperature. For competition, unlabeled
oligonucleotides (5-, 10-, 30-, and 50-fold) were added prior
to incubation with the probe. When necessary, binding reactions were
performed in the presence of sodium deoxycholate (Sigma) and/or Nonidet
P-40 (Fluka). Comparison of GAGA-binding activity between control and
stressed rats was performed using 1 µg of nuclear extract protein
prepared from pools of two anterior pituitaries. In these experiments,
protein concentrations were determined using the sensitive BCA protein
assay (Pierce) before and after adjusting the protein concentration to
0.3 µg/µl. Reaction products were electrophoresed on a 5%
polyacrylamide gel (29:1 acrylamide/bisacrylamide) in 0.5×
Tris borate/EDTA at room temperature for 90 min at 150 V. Gels were vacuum heat-dried, and bands were visualized and
quantified using the Molecular Dynamics PhosphorImager after 2 h
of exposure at room temperature.
Fast Performance Liquid Chromatography (FPLC) Fractionation of
Nuclear Extracts--
To determine the apparent molecular mass of the
GAGA-binding protein complex, ~500 µg of rat pituitary nuclear
extract in 250 µl were subjected to size-exclusion chromatography on
a Sephadex G-75 column using an FPLC system (Amersham Biosciences) at
4 °C. The column was equilibrated with buffer containing 20 mM HEPES (pH 7.9), 20% (v/v) glycerol, 100 mM
KCl, 0.2 mM EDTA, and 0.5 mM dithiothreitol at
a flow rate of 0.5 ml/min and then calibrated by multiple runs with
protein standards (ribonuclease A (13.7 kDa), chymotrypsinogen A (25 kDa), ovalbumin (43 kDa), and albumin (67 kDa); Amersham Biosciences).
A standard curve was obtained from a plot of the distribution
coefficient Kav versus log(molecular mass). The nuclear extract, diluted in the equilibration
buffer, was then run on the column, and fractions of 400 µl were
collected for analysis of GAGA-binding activity by EMSA. Prior to each
run, freshly prepared 4-(2-aminoethyl)benzenesulfonyl fluoride (0.5 mM; ICN, Costa Mesa, CA) was added to the equilibration
buffer to prevent low level proteolysis of the nuclear proteins during the runs. To test whether the apparent mass of the binding activity could be shifted in the presence of 0.8% deoxycholate (a mild ionic
detergent known to disrupt protein-protein interaction), the
fractionation was repeated in the presence of this detergent, and the
fractions were analyzed for GAGA-binding activity after reconstitution
of the proteins with Nonidet P-40. The apparent molecular masses of the
peaks of GAGA-binding activity were calculated using the standard curve.
 |
RESULTS |
Transcriptional Activity of the Rat V1bR Promoter Deletion
Constructs--
A 2.5-kb fragment of the 5'-flanking region of the rat
V1bR containing 2.1 kb upstream of the transcriptional start point, exon 1, intron 1, and 164 bp of exon 2 was previously shown to have
promoter activity in several heterologous cell lines (10). To determine
the minimal promoter sequence required for transcriptional activation,
we examined the activity of the full-length 2.5-kb fragment and several
deletion fragments linked to a luciferase reporter gene after
transfection into the hypothalamic cell line H32 (21), which expresses
V1bR mRNA. As shown in Fig.
1A, the 2.5-kb construct
(V1bRp2.5-Luc) showed 5-fold higher luciferase activity than the
pGL3-basic empty vector. In addition, as previously described in other
cell lines (10), a V1bR promoter construct lacking the intron had no
promoter activity in H32 cells (data not shown). The 830- and 670-bp
proximal fragments (V1bRp830-Luc and V1bRp670-Luc, respectively) showed
significantly higher luciferase activity than the full-length 2.5-kb
fragment, with 11- and 12.5-fold increases, respectively. To determine
whether the higher luciferase activity was due to higher promoter
activity or to an increase in transfection efficiency, we used Southern
blot analysis to evaluate the amount of plasmid DNA after transfection
of H32 cells with the V1bRp2.5-Luc, V1bRp830-Luc, and V1bRp670-Luc
constructs. The transfection efficiency of V1bRp830-Luc and
V1bRp670-Luc was similar to that of the 2.5-kb construct, indicating
that V1bRp830-Luc and V1bRp670-Luc have higher promoter activity (Fig.
1, B-D). The 470-bp proximal fragment lacking the GAGA box
had no promoter activity. This suggests the presence of repressor
elements upstream of bp 294 and that the region between bp 294 and
+377 (containing an AP2 site, the GAGA and CACA boxes, and intron 1) is
responsible for minimal promoter activity. Deletion of the GAGA box (bp
303 to 90; V1bRp830 GAGA) from the 830-bp construct
abolished promoter activity, suggesting that the GAGA box is important
for V1bR gene transcription.

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 1.
A, effect of serial deletions of the
5'-flanking region of the rat V1bR gene on basal promoter activity
after transient transfection into the hypothalamic cell line H32. Cells
were transfected with the rat V1bR promoter-luciferase constructs
indicated in the diagrams to the left. Promoter activity is expressed
as the percentage luciferase activity of each construct over the
activity of pGL3-basic. *, p < 0.01 versus
pGL3-basic; #, p < 0.01 versus
V1bRp2.5-Luc; # #, p < 0.01 versus
V1bRp830-Luc. Values represent the means ± S.E. of results from
three different experiments. The first base of the proximal
transcriptional start point (tsp) corresponds to +1.
GRE, glucocorticoid response element;
C/EBP, CAAT/enhancer-binding protein. B,
Southern blot analysis of luciferase DNA after transfection of H32
cells with V1bRp2.5-Luc, V1bRp830-Luc, and V1bRp670-Luc. C,
ethidium bromide staining of the gel used as control for DNA loading.
D, transfection efficiency of the constructs calculated as
the ratio between PhosphorImager quantification of the Southern blot
and Kodak 1D image analysis of the ethidium bromide staining. The graph
shows the results of a representative experiment.
|
|
To determine whether a recognized GAGA-binding protein can affect V1bR
promoter activity, we cotransfected the 2.5-kb V1bR promoter-luciferase
construct (V1bRp2.5-Luc) with an expression vector containing the
Drosophila GAGA factor (pCR3.1-GAGA) into H32 cells. As
shown in Fig. 2, cotransfection of
V1bRp2.5-Luc and pCR3.1-GAGA into H32 cells caused a 11-fold increase
in luciferase activity compared with cotransfection with the empty
expression vector. Cotransfection of pCR3.1-GAGA had no effect on
luciferase activity of the pGL3-basic empty reporter vector. Deletion
of the GAGA repeats in the V1bR promoter significantly decreased basal
V1bR promoter activity and abolished the stimulatory effect of the
Drosophila GAGA factor.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 2.
Effect of Drosophila
GAGA-binding protein on V1bR promoter activity. H32 cells
were cotransfected with luciferase reporter plasmid V1bRp2.5, V1bRp830,
or V1bRp830 GAGA and the expression vector containing the
Drosophila GAGA factor (pCR3.1-GAGA) or the empty expression
vector pCR3.1. Promoter activity is expressed as the percentage of
pGL3-basic luciferase activity, and data were analyzed by analysis of
variance and Fisher's Protected Least Significant Difference
test. *, p < 0.05 versus V1bRp830; #,
p < 0.01 versus respective control.
Bars represent the means ± S.E. of results from three
different experiments.
|
|
Effect of the Drosophila GAGA Factor on Endogenous Expression of
the V1bR--
Because H32 cells express endogenous V1bR, we
investigated the effect of Drosophila GAGA-binding protein
on the expression of the endogenous V1bR gene. To address this issue,
we transfected H32 cells with the pCR3.1 empty vector or the construct
containing the GAGA protein (pCR3.1-GAGA) and measured V1bR mRNA by
quantitative RT-PCR using cyclophilin as a control and under conditions
yielding PCR products for both genes in the linear range. As shown in
Fig. 3 (A and B),
transfection of Drosophila GAGA had no effect on the 250-bp
cyclophilin band, but it increased the 509-bp band corresponding to the
V1bR mRNA by 6-fold. Similar increases in endogenous V1bR mRNA
were found after transfection of MCF-7 cells with the
Drosophila GAGA factor (data not shown).

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 3.
Effect of GAGA-binding protein on endogenous
V1bR mRNA expression in H32 cells. A, cells were
transfected with the empty expression vector pCR3.1 or pCR3.1-GAGA.
V1bR and cyclophilin (Cyph) mRNAs were measured by
quantitative RT-PCR. Samples without the reverse transcription step
( RT) were used as controls to exclude genomic
contamination. B, quantitative analysis of the bands was
performed using the Kodak 1D image analysis system. Bars
represent the means ± S.E. of values from three experiments. *,
p < 0.05 versus cells transfected with the
empty vector.
|
|
V1bR GAGA Repeats Bind Nuclear Proteins--
To determine whether
the V1bR GAGA box interacts with pituitary nuclear proteins, we
performed EMSA after incubation of pituitary nuclear extracts with
(GAGA)3 or (GAGA)5 repeat oligonucleotides flanked by the sequences found in the V1bR promoter. A shifted band of
increasing intensity was observed with increasing amounts of nuclear
extract from 0.5 to 3 µg; binding maintained a plateau up to 10 µg
of protein. A similar binding pattern was observed using either the
(GAGA)3 or (GAGA)5 repeat probe, but the
amount of probe shifted was higher for the (GAGA)5
oligonucleotide than for the (GAGA)3 repeats (Fig.
4).

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 4.
A, shown is the protein
concentration dependence of the binding of pituitary nuclear proteins
to radiolabeled (GAGA)3 (3x-GAGA) and
(GAGA)5 (5x-GAGA) repeat oligonucleotides.
B, quantification of the intensity of the shifted bands was
performed using the PhosphorImager. The graph shows the results of
a representative experiment. B/Tx100, % bound/total.
|
|
Binding of pituitary nuclear extracts to radiolabeled
(GAGA)3 and (GAGA)5 repeats was effectively
competed by the homologous unlabeled oligonucleotide (Fig.
5A). For both probes, addition of five times the molar concentration of unlabeled oligonucleotides caused ~80% inhibition of the shifted bands. A progressive but slower binding inhibition was observed with higher concentrations of
unlabeled oligonucleotide, with ~5% of the binding remaining in the
presence of 50 times the molar concentration of competitors (Fig.
5B). In contrast, no inhibition of the binding of the
(GAGA)3 probe to nuclear proteins was observed after
addition of a mutant oligonucleotide (Fig. 5C). Furthermore,
the radiolabeled mutant oligonucleotide did not bind nuclear proteins
(Fig. 5C).

View larger version (35K):
[in this window]
[in a new window]
|
Fig. 5.
Specificity of the binding of pituitary
nuclear extracts to (GAGA)3 and (GAGA)5
oligonucleotides. A, inhibition of binding by
addition of increasing amounts of unlabeled homologous oligonucleotide;
B, quantification of the intensity of the bands in the gel
shown in A; C, EMSA following incubation of
pituitary nuclear extracts with (GAGA)3
(3x-GAGA) or a (GAGA)3 mutant oligonucleotide
(3x-GAGAmut) used as a probe or competitor.
5x-GAGA, (GAGA)5; AU, arbitrary
units.
|
|
The time course of the binding of GAGA repeat oligonucleotides to
pituitary nuclear proteins is shown in Fig.
6A. Binding was already marked
after 3 min, reached equilibrium by 18 min, and maintained a plateau
for up to 1 h. Consistent with the data in Fig. 4, using equimolar
concentrations of probe, the percentage of radiolabeled probe shifted
was much higher for the (GAGA)5 repeat oligonucleotide.
Dissociation of DNA-protein complexes by addition of the competitor at
the time when binding of radiolabeled (GAGA)3
oligonucleotides to pituitary nuclear extracts had reached equilibrium
was very rapid. One min after addition of unlabeled (GAGA)3
and (GAGA)5 repeats, 55 and 63% binding inhibition was already observed, respectively (Fig. 6B). A slow further
decline in binding was observed from 1 to 16 min after addition of the competitor. GAGA-binding activity was not confined to pituitary nuclear
proteins, but was present in nuclear extracts from a number of rat
tissues (Fig. 7). The highest binding was
observed in the brain cortex, hypothalamus, and kidney, followed by
moderate binding in the pituitary, liver, thymus, and ovary and very
low binding in the spleen.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 6.
A, time course of the binding of
radiolabeled (GAGA)3 or (GAGA)5 repeats to
pituitary nuclear extract. Quantification of the shifted bands was
performed using the PhosphorImager. B, binding dissociation
curve in the presence of unlabeled (GAGA)3
(3x-GAGA) or (GAGA)5 (5x-GAGA)
repeats added at binding equilibrium. The intensity of shifted bands
was quantified, and the results are expressed as the percentage of
total binding in the absence of competitor. B/Tx100, % bound/total.
|
|

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 7.
Gel shift assay (A) and
quantitative analysis of bands (B) following
incubation of the (GAGA)3 repeat probe with nuclear
extracts from different rat tissues. AU, arbitrary
units.
|
|
Effect of Acute Stress on GAGA-binding Activity--
To determine
the possible involvement of GAGA-binding proteins in V1bR transcription
in vivo, we used EMSA to compare the GAGA-binding activity
of pituitary nuclear proteins from controls and rats subjected to
restraint stress, a condition associated with up-regulation of V1bR
expression. PhosphorImager analysis of the shifted bands revealed an
increase in binding of pituitary nuclear proteins from stressed rats to
radiolabeled GAGA oligonucleotides compared with nuclear extracts from
non-stressed control rats. The increases in binding were minor by 15 min, reached a significant 40% by 30 min, and declined again by 90 min
(Fig. 8). In contrast, no increases in
intensity of the shifted bands were observed in EMSA using liver
nuclear extracts (data not shown).

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 8.
Effect of restraint stress on GAGA-binding
activity of pituitary nuclear proteins evaluated by EMSA. Rats
were killed 15, 30, and 90 min after initiation of the stress.
Bars represent the means ± S.E. of the values obtained
by PhosphorImager analysis of the shifted bands in three experiments
using pools of two pituitaries/experimental group. *, p < 0.01 compared with control (analysis of variance, followed by
Fisher's test).
|
|
GAGA-binding Activity of Pituitary Nuclear Extracts Corresponds to
Protein Complexes--
To determine whether the GAGA-binding activity
observed in pituitary nuclear extracts involves a single protein or a
protein complex, binding of the nuclear extracts to the radiolabeled
GAGA oligonucleotide was performed in the presence of increasing
concentrations of sodium deoxycholate. It has been shown that this
treatment dissociates protein-protein complexes without affecting
DNA-protein interaction, an effect that is reversible by addition of
the nonionic detergent Nonidet P-40 (22, 23). As shown in Fig.
9A, disruption of
protein-protein interaction by deoxycholate inhibited the binding of
nuclear proteins to DNA; shifted bands were markedly decreased in the
presence of 0.8% deoxycholate and were abolished with 1.2%. Addition
of 1% Nonidet P-40 on its own to the binding reaction had no effect on
the shifted bands (Fig. 9A, last lane), but
considerably reduced the inhibitory effect of deoxycholate (Fig.
9B). To determine whether dissociation of
protein-protein complexes by deoxycholate affected the absolute binding
activity or the affinity of protein monomers for DNA, we incubated
increasing amounts of pituitary nuclear extract with
(GAGA)3 repeats in the presence or absence of 0.8%
deoxycholate. As shown in Fig. 10
(A and B), the inhibitory effect of deoxycholate
was not overcome by increasing protein concentrations, suggesting that
protein complex formation is essential for DNA binding.

View larger version (41K):
[in this window]
[in a new window]
|
Fig. 9.
Effect of dissociation of protein complexes
by deoxycholate on binding of pituitary nuclear extracts to GAGA repeat
oligonucleotides. A, EMSA following incubation of
nuclear extracts with increasing concentrations of sodium deoxycholate
(DOC) or 1% Nonidet P-40; B, gel shift assay
following the binding reaction in the presence of deoxycholate with or
without 1% Nonidet P-40 added to neutralize the effect of
deoxycholate.
|
|

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 10.
Increasing protein concentration does not
restore binding of nuclear extracts to GAGA oligonucleotides in the
presence of deoxycholate. A, EMSA following binding of
(GAGA)3 oligonucleotides to 1-10 µg of nuclear extract
with and without 0.8% deoxycholate (DOC); B,
quantitative analysis of the shifted bands. AU, arbitrary
units.
|
|
The apparent molecular mass of the protein complex was examined by
size-exclusion chromatography of pituitary nuclear extracts in the
presence or absence of sodium deoxycholate. In the absence of
deoxycholate, the binding activity was observed in the included volume
with a peak in fraction 21 (Fig. 11,
A and B). The apparent molecular mass of this
binding activity was calculated to be ~127 ± 12 kDa. There was
no binding detected in the fractions from the run performed in the
presence of 0.8% deoxycholate (data not shown). However, when Nonidet
P-40 was added to reconstitute protein complexes, the binding activity
was then observed in fractions 21-25, with a peak in fraction 23 corresponding to a calculated apparent molecular mass of ~70 kDa
(Fig. 11C). Collectively, these data suggest that a
protein complex of ~127 ± 12 kDa is responsible for DNA binding
to GAGA repeats and that this protein complex may include two subunits,
each with an apparent molecular mass of ~70 kDa.

View larger version (44K):
[in this window]
[in a new window]
|
Fig. 11.
A, gel shift analysis of FPLC fractions
from pituitary nuclear extract after incubation with
(GAGA)3 repeats. Control, pituitary nuclear
extract not subjected to fractionation. B, gel shift
analysis of pituitary nuclear extract pretreated with 0.8% sodium
deoxycholate before FPLC fractionation. After fractionation, protein
complexes were reconstituted by addition of 1% Nonidet P-40 before
binding to the (GAGA)3 repeat probe. C,
quantification of the intensity of the shifted bands for the native
protein ( ) and for the sodium deoxycholate
(DOC)/Nonidet P-40-treated extracts (· · · ·).
The apparent molecular mass of the bound protein was calculated using
the formula y = 1.163 0.225x
(r2 = 0.99, where x = log(molecular mass) and y = Kav), obtained after calibration of the Sephadex
G-75 column with different standards. AU, arbitrary
units.
|
|
 |
DISCUSSION |
The recent characterization of the 5'-flanking region of the V1bR
has made it possible to study the transcriptional regulation of the
receptor. Previous studies in this laboratory have shown that a 2.5-kb
V1bR gene fragment (bp 2161 to +377 from the proximal transcriptional
start point, corresponding to 2.1 kb of the putative promoter, exon 1, intron 1, and 164 bp of exon 2) has promoter activity in cell lines not
expressing the V1bR (10). We now show that this same DNA fragment is
capable of driving reporter gene expression in the hypothalamic cell
line H32 (21), which expresses the
V1bR.2 The increase in
luciferase activity after deletion of sequences upstream of bp 294
suggests that the shorter fragments have higher promoter activity. The
demonstration by Southern blotting of similar transfection efficiency
for all constructs strongly suggests that the region between bp 294
and 2161 of the V1bR promoter contains repressor elements. Previous
studies in AtT-20 cells have suggested the presence of repressors in
the V1bR promoter (10). It is also clear from the data that the GAGA
box is essential for full promoter activity.
The proximity of an inverted GAGA box to the transcriptional start
point of the V1bR gene, in conjunction with the dramatic decrease in
basal promoter activity following deletion of the GAGA box, suggested
to us that this sequence is important for the transcriptional
regulation of the receptor (10). The present study provides evidence
supporting this hypothesis. First, a recognized GAGA-binding protein,
the Drosophila GAGA factor, stimulates V1bR promoter
activity. This increase in V1bR promoter activity by the
Drosophila GAGA factor is probably mediated by the GAGA box in the promoter because the effect was abolished by deletion of bp
303 to 90 (V1bRp830 GAGA), which include the main stretch of GAGA repeats, preserving the upstream regulatory elements. In
addition, the fact that transfection of the GAGA factor increased the
expression of endogenous V1bR provides strong evidence that a
GAGA-binding protein is involved in the regulation of the V1bR.
It has been reported that a GAGA-binding protein is involved in the
transcriptional regulation of other vertebrate genes, including the
human type 1 angiotensin II receptor gene, the rat serine protease
inhibitor-1 gene, and the Xenopus stromelysin-3 gene
(16-18). In the case of serine protease inhibitor-1 and the type 1 angiotensin II receptor, GAGA-binding activity is stimulated by growth
factors, and the GAGA box appears to mediate growth factor-mediated
gene transcription (16, 17). GAGA box-mediated transcriptional
activation of the V1bR promoter could also involve growth factors
because recent experiments in our laboratory have shown increases in
GAGA-binding activity after incubation of H32 cells with the epidermal
growth factor.3 The marked
reduction in basal promoter activity following deletion of the main
GAGA box from the V1bR minimal promoter suggests that the GAGA repeats
are required for initiation of transcription, as has been postulated
for type 1 angiotensin II receptor and serine protease inhibitor
genes (17, 24).
The shift of radiolabeled GAGA repeat oligonucleotide probes by
pituitary nuclear proteins indicates that endogenous nuclear proteins
have the ability to bind to the GAGA box of the V1bR. The markedly
higher binding activity of the (GAGA)5 repeat compared with
the (GAGA)3 repeat could be due to higher affinity of the larger repeats for the binding proteins. However, this possibility is
not supported by the kinetics of interaction between the two probes and
nuclear extracts, with similar association and dissociation patterns.
The GAGA box of the V1bR, comprising 134 bp, is unusually large.
Although the consensus GAGA binding sequence consists of ~3.5
GA repeats, atypical sequences frequently found in other promoters have also been shown to bind GAGA-binding proteins (16-18). The V1bR promoter contains several short sequences for GAGA upstream of
the major GAGA box, which may explain a minor stimulatory effect of the
cotransfected GAGA factor on promoter activity of the construct lacking the GAGA box.
This study clearly shows that pituitary nuclear proteins can interact
with GAGA repeats. The finding of GAGA-binding activity in a number of
tissues in the rat is consistent with the view that GAGA repeats may be
involved in the transcriptional regulation of a variety of mammalian
genes (25). The rat GAGA-binding protein is structurally different from
the Drosophila GAGA factor because an antibody recognizing
the latter (24, 26) failed to supershift the band in EMSA (data not
shown). Although the exact identity of the GAGA-binding protein
interacting with the V1bR promoter remains to be elucidated, it is
clear from the data that DNA-binding activity requires the formation of
a protein complex, which can be dissociated by deoxycholate. Although
the native nuclear protein complex showed an apparent molecular mass of
~127 ± 12 kDa after size-exclusion chromatography, Nonidet P-40
reconstitution of the complex after fractionation of the
deoxycholate-dissociated extract showed that the binding activity was
recovered in the ~70-kDa range. This indicates that all components of
the complex were eluted in the same fractions and suggests that the
active complex may correspond to a homo- or heterodimer of proteins of ~70 kDa. The present findings are consistent with characteristics described for Drosophila GAGA-binding proteins (25). A
number of cDNA species have been described for the
Drosophila GAGA factor, encoding isoforms of 70-75
kDa (GAGA-519) and 80-90 kDa (GAGA-581). The two isoforms have been
shown to form both homo- and heteromeric complexes (25).
An important question is whether GAGA-binding activity in nuclear
extracts in the pituitary corticotroph is regulated during physiological conditions leading to changes in V1bR expression (6).
Because we have previously shown that restraint stress causes
rapid increases in pituitary V1bR mRNA, it was important to
determine whether this stress paradigm could increase GAGA-binding activity in the pituitary. The present demonstration that pituitary extracts from stressed rats indeed display higher GAGA-binding activity
supports a role for the GAGA box in the physiological regulation of
V1bR transcription. Moreover, this effect appears to be specific for
the pituitary because no differences between control and stressed rats
were found in EMSA analysis of liver nuclear proteins. The effect of
stress on GAGA-binding activity of pituitary extracts was relatively
small. Because corticotrophs represent <10% of the pituitary cell
population (27), GAGA-binding proteins present in other pituitary cell
types would mask changes in GAGA-binding activity in the corticotroph.
It is noteworthy that the increases in GAGA-binding activity during
stress were early (30 min) and transient. This is consistent with the
possibility of activation of GAGA-binding proteins by phosphorylation,
as has been reported for growth factor-mediated regulation of the type 1 angiotensin II receptor promoter (17).
In conclusion, these studies provide evidence that GAGA-binding
proteins stimulate transcription of the V1bR by interaction with GAGA
repeats present in the promoter of the V1bR. This is supported by the
marked increase in V1bR promoter-driven luciferase after cotransfection
with the GAGA factor, the ability of transfected GAGA protein to
activate endogenous V1bR expression, and the ability of endogenous
pituitary nuclear proteins to bind GAGA repeat oligonucleotides. The
binding protein corresponds to a protein complex with an apparent molecular mass of ~127 kDa, which may comprise two 70-kDa subunits.
 |
ACKNOWLEDGEMENTS |
We would like to thank Dr. Jordi Bernues,
Instituto de Biologia Molecular de Barcelona, Consell Superior
d'Investigacions Cientifiques, Barcelona, Spain, for the Drosophila
GAGA cDNA; Dr. Carl Wu, NCI-NIH, for the Drosophila GAGA factor
antibody; Dr. Joachim Spiess, Max Planck Institute, Göttingen,
Germany, for the hypothalamic cell line, H32, and Dr. Stoney
Simons, Jr., for very helpful discussions.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence should be addressed: Section on Endocrine
Physiology, DEB, NICHD, NIH, Bldg. 10, Rm. 10N262, 10 Center Dr., MSC
1862, Bethesda, MD 20892-1862. Tel.: 301-496-7656; Fax: 301-402-6163;
E-mail: volpis@mail.nih.gov.
Published, JBC Papers in Press, May 21, 2002, DOI 10.1074/jbc.M201508200
2
M. Nikodemova, S. Volpi, J. Spiess, and
G. Aguilera, unpublished data.
3
S. Volpi and G. Aguilera, unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
ACTH, adrenocorticotropic hormone;
V1bR, V1b receptor;
RT, reverse
transcription;
EMSA, electrophoretic mobility shift assay;
FPLC, fast
performance liquid chromatography.
 |
REFERENCES |
| 1.
|
Antoni, F. A.
(1993)
Front. Neuroendocrinol.
14,
76-122[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Aguilera, G.
(1994)
Front. Neuroendocrinol.
15,
321-350[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Jard, S.,
Barberis, C.,
Audigier, S.,
and Tribollet, E.
(1987)
Prog. Brain Res.
72,
173-187[Medline]
[Order article via Infotrieve]
|
| 4.
|
Gallo-Payet, N.,
Guillon, G.,
Balestre, M. N.,
and Jard, S.
(1986)
Endocrinology
119,
1042-1047[Abstract/Free Full Text]
|
| 5.
|
Lolait, S. J.,
O'Carroll, A. M.,
McBride, O. W.,
Konig, M.,
Morel, A.,
and Brownstein, M. J.
(1992)
Nature
357,
336-339[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Rabadan-Diehl, C.,
Lolait, S. J.,
and Aguilera, G.
(1995)
J. Neuroendocrinol.
7,
903-910[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Aguilera, G.,
Pham, Q.,
and Rabadan-Diehl, C.
(1994)
J. Neuroendocrinol.
6,
299-304[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Aguilera, G.,
and Rabadan-Diehl, C.
(2000)
Exp. Physiol.
85,
19S-26S[Abstract]
|
| 9.
|
Nomura, A.,
Iwasaki, Y.,
Saito, M.,
Aoki, Y.,
Yamamori, E.,
Ozaki, N.,
Tachikawa, K.,
Mutsuga, N.,
Morishita, M.,
Yoshida, M.,
Asai, M.,
Oiso, Y.,
and Saito, H.
(2001)
Am. J. Physiol.
280,
E780-E787[Abstract/Free Full Text]
|
| 10.
|
Rabadan-Diehl, C.,
Lolait, S.,
and Aguilera, G.
(2000)
J. Neuroendocrinol.
12,
437-444[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Farkas, G.,
Gausz, J.,
Galloni, M.,
Reuter, G.,
Gyurkovics, H.,
and Karch, F.
(1994)
Nature
371,
806-808[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Biggin, M. D.,
and Tjian, R.
(1988)
Cell
53,
699-711[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Gilmour, D. S.,
Thomas, G. H.,
and Elgin, S. C.
(1989)
Science
245,
1487-1490[Abstract/Free Full Text]
|
| 14.
|
Soeller, W. C., Oh, C. E.,
and Kornberg, T. B.
(1993)
Mol. Cell. Biol.
13,
7961-7970[Abstract/Free Full Text]
|
| 15.
|
Bhat, K. M.,
Farkas, G.,
Karch, F.,
Gyurkovics, H.,
Gausz, J.,
and Schedl, P.
(1996)
Development
122,
1113-1124[Abstract]
|
| 16.
|
Simar-Blanchet, A. E.,
Legraverend, C.,
Thissen, J. P.,
and Le Cam, A.
(1998)
Mol. Endocrinol.
12,
391-404[Abstract/Free Full Text]
|
| 17.
|
Wyse, B. D.,
Linas, S. L.,
and Thekkumkara, T. J.
(2000)
J. Mol. Endocrinol.
25,
97-108[Abstract]
|
| 18.
|
Li, J.,
Liang, V. C.,
Sedgwick, T.,
Wong, J.,
and Shi, Y. B.
(1998)
Nucleic Acids Res.
26,
3018-3025[Abstract/Free Full Text]
|
| 19.
|
Granok, H.,
Leibovitch, B. A.,
Shaffer, C. D.,
and Elgin, S. C.
(1995)
Curr. Biol.
5,
238-241[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Hauger, R. L.,
Lorang, M.,
Irwin, M.,
and Aguilera, G.
(1990)
Brain Res.
532,
34-40[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Mugele, K.,
Kugler, H.,
and Spiess, J.
(1993)
DNA Cell Biol.
12,
119-126[Medline]
[Order article via Infotrieve]
|
| 22.
|
Baeuerle, P. A.,
and Baltimore, D.
(1988)
Cell
53,
211-217[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Kupfer, S. R.,
Marschke, K. B.,
Wilson, E. M.,
and French, F. S.
(1993)
J. Biol. Chem.
268,
17519-17527[Abstract/Free Full Text]
|
| 24.
|
Leverrier, S.,
Cinato, E.,
Paul, C.,
Derancourt, J.,
Bemark, M.,
Leanderson, T.,
and Legraverend, C.
(2000)
Biol. Chem. Hoppe-Seyler
381,
1031-1040
|
| 25.
|
Benyajati, C.,
Mueller, L., Xu, N.,
Pappano, M.,
Gao, J.,
Mosammaparast, M.,
Conklin, D.,
Granok, H.,
Craig, C.,
and Elgin, S.
(1997)
Nucleic Acids Res.
25,
3345-3353[Abstract/Free Full Text]
|
| 26.
|
Tsukiyama, T.,
Becker, P. B.,
and Wu, C.
(1994)
Nature
367,
525-532[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Childs, G. V.,
Lloyd, J. M.,
Rougeau, D.,
and Unabia, G.
(1988)
Endocrinology
123,
2885-2895[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
D. L. Sackett, L. Ozbun, E. Zudaire, L. Wessner, J. M. Chirgwin, F. Cuttitta, and A. Martinez
Intracellular Proadrenomedullin-Derived Peptides Decorate the Microtubules and Contribute to Cytoskeleton Function
Endocrinology,
June 1, 2008;
149(6):
2888 - 2898.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-J. Han, W.-Y. Hu, O. Chernaya, N. Antic, L. Gu, M. Gupta, M. Piano, and P. de Lanerolle
Increased Myosin Light Chain Kinase Expression in Hypertension: Regulation by Serum Response Factor via an Insertion Mutation in the Promoter
Mol. Biol. Cell,
September 1, 2006;
17(9):
4039 - 4050.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Volpi, Y. Liu, and G. Aguilera
Vasopressin increases GAGA binding activity to the V1b receptor promoter through transactivation of the MAP kinase pathway.
J. Mol. Endocrinol.,
June 1, 2006;
36(3):
581 - 590.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. A. Miyakawa, M. de Lourdes Junqueira, and J. E. Krieger
Identification of two novel shear stress responsive elements in rat angiotensin I converting enzyme promoter
Physiol Genomics,
April 13, 2004;
17(2):
107 - 113.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|